<DOC>
	<DOCNO>NCT03066115</DOCNO>
	<brief_summary>Elucidating cerebrovascular control mechanisms physiologic stress may help identify novel therapeutic target aim prevent reduce impact cerebrovascular disease . The physiological stressor hypoxia hypercapnia utilized elicit increase cerebral blood flow ( CBF ) , intravenously infuse drug allow test potential mechanism cerebrovascular control . Specifically , contribution nitric oxide synthase ( NOS ) , cyclooxygenase ( COX ) , reactive oxygen specie ( ROS ) hypoxic hypercapnic increase CBF examine . The concept mechanism interact compensatory fashion ensure adequate CBF hypoxia hypercapnia also test . ~25 young , healthy men woman test rest hypoxia hypercapnia . Subjects participate two randomize , counterbalance study visit follow condition : inhibition NOS , NOS-COX , NOS-COX-ROS inhibition COX , COX-NOS , COX-NOS-ROS . During hypoxia , arterial oxygen saturation lower 80 % end-tidal carbon dioxide maintain basal level . During hypercapnia arterial carbon dioxide increase ~10 mmHg basal level arterial oxygen saturation maintain . Blood flow velocity measure transcranial Doppler ultrasound anterior ( middle cerebral artery ; MCA ) posterior ( basilar artery ; BA ) circulation surrogate CBF . It hypothesize NOS COX independently contribute hypoxic hypercapnic vasodilation MCA BA , combine NOS-COX contribute hypoxic hypercapnic vasodilation MCA BA great extent either NOS COX alone , NOS-COX-ROS contribute hypoxic hypercapnic vasodilation MCA BA great extent NOS-COX .</brief_summary>
	<brief_title>Impact NOS , COX , ROS Inhibition Cerebral Blood Flow Regulation</brief_title>
	<detailed_description>Specific Aims : 1A . Determine independent contribution NOS COX hypoxic hypercapnic vasodilation MCA young , healthy adult . 1B . Determine combined contribution NOS COX hypoxic hypercapnic vasodilation MCA young , healthy adult . 1 . C. Determine combine contribution NOS , COX , ROS hypoxic hypercapnic vasodilation MCA young , healthy adult . 2 . A . Determine independent contribution NOS COX hypoxic hypercapnic vasodilation BA young , healthy adult . 2B . Determine combined contribution NOS COX hypoxic hypercapnic vasodilation BA young , healthy adult . 2C . Determine combined contribution NOS , COX , ROS hypoxic hypercapnic vasodilation BA young , healthy adult . Initial Screening : A phone screening questionnaire determine whether potential subject meet preliminary eligibility criterion . Potentially eligible subject invite additional in-person screening . Subjects need come screening visit fast ( except water ) minimum 10 hour . Laboratory screen procedure include : 1 . Informed consent 2 . Health history questionnaire 3 . Physical activity questionnaire 4 . Urine pregnancy test ( female ) 5 . Venous blood draw 6 . DEXA scan ( dual energy x-ray absorptiometry ) Study Design : Eligible subject complete 2 study visit examine hypoxic hypercapnic response four condition : control , NOS inhibition COX inhibition , NOS COX inhibition NOS , COX , ROS inhibition . During visit 1 , subject receive L-NMMA ( NG-Monomethyl-L-arginine ; NOS inhibition ) , ketorolac ( COX inhibition ) , ascorbic acid ( ROS inhibition ) . During visit 2 , subject receive ketorolac , L-NMMA , ascorbic acid . Study visit conduct randomized , counterbalanced order drug infuse intravenously . Hypoxia elicit SPO2~80 % determine pulse oximetry hypercapnia increase end-tidal CO2 ( PETCO2 ) ~10 mmHg baseline . Throughout visit , subject monitor heart rate , blood pressure , pulse oximetry oxygen saturation , respiratory gas , ventilation , CBF velocity . After instrumentation baseline data collection , hypoxic hypercapnic trial commence middle cerebral artery velocity ( MCAv ) , basilar artery velocity ( BAv ) , respiratory , cardiovascular variable record . All trial separate 10-minutes quiet rest breathing room air randomize due order time drug infusion require explore aim . Due difficulty insonating BA , serve exploratory aim deem necessary outcome study completion . Experimental Methods Intervention Plan : Transcranial Doppler Ultrasound ( TCD ) MCAv measure via transtemporal window BAv measure transforaminal window 2-MHz ( megahertz ) transcranial Doppler ultrasound probe . In approximately 30 % individual BA identify ; therefore , insonation MCA alone deem sufficient proceed study case BA locate . Measurements Height weight measure calculate body mass index ( BMI ) . Waist hip circumference measure indicator regional adiposity . DEXA scan use determination body composition . Venous blood sample obtain determination blood chemistry value . During visit , subject study semi-recumbent position instrument continuous measurement heart rate ( 3-lead ECG ) , pulse oximetry oxygen saturation ( SPO2 , pulse oximeter ) , blood pressure ( MABP , automate physiological monitor ) . Hemodynamic parameter continuously measure finger plethysmography . Inspiratory expiratory gas measure gas analyzer respiratory flow determine heated pneumotachometer . Hypoxia Hypoxia use cause cerebral vasodilation resting , semi-recumbent condition . Three isocapnic hypoxia trial perform per study visit . Subjects inspire two-way non-rebreathing valve , connect gas mixer , supply medical grade pressurize oxygen ( O2 ) , carbon dioxide ( CO2 ) , nitrogen ( N2 ) . After 3-minutes baseline room air breathing , hypoxia introduce decrease inspire O2 ( ~11 % O2 ) elicit sustain 3-minutes SPO2~80 % determine pulse oximeter . After 3-minutes baseline steady state hypoxia , 5-minute drug loading period ( L-NMMA , ketoroloc , ascorbic acid ) , follow 5-minute drug maintenance period . Hypoxia maintain time , total hypoxia duration ~15-minutes per hypoxia trial . Isocapnia achieve addition CO2 inspire gas . End-tidal CO2 ( PETCO2 ) show valid predictor arterial blood CO2 level . Prior data lab indicate steady state hypoxia achieve within 3 minute . Additionally , hypoxia elicit SPO2~80 % examine cerebral vessel relatively low cerebrovascular sensitivity less severe hypoxia ( SPO2~90 % ) . A total 3 hypoxia trial conduct per study visit yield ~45 minute steady state hypoxia . Hypercapnia An increase systemic CO2 powerful signal increase blood flow within cerebral circulation . A total 4 hypercapnic trial perform study visit . Subjects inspire three-way slide rebreathing valve attach latex balloon contain hyperoxic ( O2=40 % ) , hypercapnic ( CO2=3 % ) gas mixture balance N2 . The balloon fill volume exceed estimate vital capacity ( determined age , sex , height ) 1-liter . After 3-minutes baseline room air breathing , hypercapnia commence slide three-way rebreathing valve room air attach latex balloon . During hypercapnia , PETCO2 increase ( ~10 mmHg baseline value ) , inspire O2 fall room air percentage 21 % . Hypercapnia sustain ( ~2-minutes ) PETCO2 value reach ~10 mmHg baseline value , subject begin breathe room air . PETCO2 use reliable , non-invasive measure arterial CO2 . A total 4 hypercapnic trial conduct per study visit yield ~ 8 minute hypercapnia per study visit . Intravenous Catheter Trained lab personnel place two intravenous catheter ( one arm ) study visit . One catheter use intravenous infusion study drug ( L-NMMA , Ketorolac , Ascorbic Acid ) . The second catheter use draw intermittent blood sample 8-specific time point throughout study visit ensure pharmaceutical efficacy examine systemic physiologic blood variable interest . The catheter use blood draw keep patent 0.9 % saline drip . If one IV catheter place one fails , study proceed drug infusion blood draw occur single catheter . Intravenous L-NMMA Infusion Intravenous L-NMMA non-FDA approve drug use , commonly utilized research setting . Intravenous infusion L-NMMA use inhibit enzyme NOS responsible formation NO . L-NMMA lyophilized powder dilute saline . In current study , intravenous L-NMMA administer via 3 mg kg-1 load dose 5-minutes ( 36 mg kg-1 hr-1 ) , follow maintenance dose 1 mg kg-1 hr-1 remainder study . Considering typical 75 kg individual result load dose 225mg maintenance dose ( ~112min ) 140mg total 365 mg L-NMMA throughout duration study , L-NMMA first study drug infuse ( L-NMMA infuse HX1 , HX2 , HX3 HC2 , HC3 , HC4 ) . During visit L-NMMA second study drug infuse ( L-NMMA infuse HX2 , HX3 HC3 , HC4 ) total dose less maintenance infusion ( ~67 min ) reduce ~45 minute total 309 mg L-NMMA . The load dose L-NMMA equivalent use prior study investigate contribution NOS hypoxic cerebral vasodilation maintenance dose absolute amount L-NMMA infuse less previously utilize . Intravenous Ketorolac Infusion Intravenous ketorolac FDA approve non-steroidal anti-inflammatory drug use treatment pain . Ketorolac use non-specifically inhibit enzyme cyclooxygenase responsible formation vasoactive prostaglandin ( prostacyclin , thromboxane ) . Inhibition prostaglandin synthesis hypoxia allow assessment contribution vasoactive prostaglandin hypoxic vasodilation . Common intravenous dos ketorolac 15 mg 30 mg bolus infusion ; however , ketorolac dose relative body mass . Ketorolac intravenously administer via 0.3 mg kg-1 loading dose 5 minute ( 3.6 mg kg-1 hr-1 ) minimum load dose 15 mg . This follow maintenance dose 0.03 mg kg-1 hr-1 remainder study . Considering typical 75 kg individual result load dose 22.5 mg maintenance dose ( ~112min ) 4.2 mg total 26.7 mg ketorolac throughout duration study , ketorolac first study drug infuse ( ketorolac infuse HX1 , HX2 , HX3 HC2 , HC3 , HC4 ) . During visit ketorolac second study drug infuse ketorolac infuse HX2 , HX3 HC3 , HC4 ) total dose less maintenance infusion ( ~67 min ) reduce ~45 minute total 25 mg ketorolac . Similar dos ketorolac show reduce whole body prostanoids reduce perioperative pain . Plasma ketorolac concentration peak within ~3 minute follow intravenous administration terminal half-life 5.6 hour . Intravenous Ascorbic Acid Infusion Intravenous ascorbic acid FDA-approved . Ascorbic acid intravenously administer acutely reduce ROS . Ascorbic acid administer via load dose 0.035 g kg fat-free mass-1 5-minutes ( 0.42 g kg fat-free mass-1 hr-1 ) . Followed maintenance dose 0.060 g kg fat-free mass-1 hr-1 remain study time course ( ~20 minute ) continue suppression reactive oxygen specie . Considering 75 kg individual fat-free tissue mass ~55kg ( base upon previous young , healthy subject lab ) , subject receive ~ 3.025 g Ascorbic acid course study visit . Plasma Assays ~10 mL blood drawn screen visit component study eligibility . Screening blood sample analyze fast venous glucose , creatinine , total cholesterol , HDL cholesterol , LDL cholesterol , triglyceride . Venous blood sample draw 8 time point study protocol via venous catheter . Each blood draw 10 mL , total 80 mL . Blood centrifuge plasma serum drawn store -80ºC . Efficacy COX inhibition determine measurement ( EIA ) circulate COX metabolites 6-keto-prostaglandin F1α ( stable marker PGI2 ) thromboxane B2 ( stable marker TXA2 ) . Efficacy ROS inhibition determine plasma vitamin C concentration oxidize low-density lipoprotein ( oxLDL ) serve systemic marker oxidative stress . Acute intravenous Ascorbic acid administration show decrease oxLDL healthy adult . Efficacy NOS inhibition determine sum nitrite nitrate ( NOx ) , consider index NO production .</detailed_description>
	<mesh_term>Anoxia</mesh_term>
	<mesh_term>Hypercapnia</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>omega-N-Methylarginine</mesh_term>
	<criteria>1 . Age : 18 ≤ year ≤ 45 2 . Free disease otherwise healthy determine health history questionnaire 3 . Not currently take medication exception birth control determine health history questionnaire 4 . Low moderate physical activity permit assessed physical activity questionnaire ( ≤ 4 hour physical activity/week ) 5 . Body mass index ( BMI ) &lt; 25 kg/m2 6 . Resting blood pressure &lt; 140/ &lt; 90 mmHg ( low three measure ) 7 . Resting heart rate &lt; 100 bpm 8 . Resting pulse oximetry oxygen saturation ( SPO2 ) &gt; 95 % 9 . Fasting venous blood value ( average two measure ) 1 . Glucose &lt; 100 mg/dL 2 . Creatinine &lt; 1.5 mg/dL 3 . Total cholesterol &lt; 200 mg/dL i. HDL cholesterol &gt; 40 mg/dL ( men ) ii . HDL cholesterol &gt; 50 mg/dL ( woman ) iii . LDL cholesterol &lt; 130 mg/dL d. Triglycerides &lt; 150 mg/dL 10 . Subjects must willing report laboratory study day complete 1 . Minimum 10hour fast 2 . Minimum 18hours abstention exercise , alcohol , caffeine , nonsteroidal antiinflammatory drug ( i.e . aspirin , ibuprofen , naproxen ) 11 . Additionally , woman 1 . Have regular menstrual cycle ( selfreport ) 2 . Be study ( study visit 1 study visit 2 ) day 15 menstrual cycle ( self report ) . 1 . Coronary artery disease 2 . Stroke 3 . Heart attack 4 . Heart valve disease 5 . Congestive heart failure 6 . Previous heart surgery 7 . Lung disease 8 . Peripheral vascular disease 9 . Gastrointestinal ( GI ) bleed 10 . Allergy Intolerance Aspirin NSAIDS 11 . History renal/kidney disease , insufficiency , injury 12 . Smoke use tobacco within last year 13 . Subject abnormality contraindication study participation , cover eligibility criterion . Additionally , woman exclude 1 . Pregnant ( determine urine pregnancy test screen study day ) 2 . Currently breastfeed ( selfreport ) 3 . Postmenopausal ( selfreport )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cerebral blood flow</keyword>
	<keyword>Cyclooxygenase</keyword>
	<keyword>Nitric oxide synthase</keyword>
	<keyword>Reactive Oxygen Species</keyword>
</DOC>